A self-assembled peptide was discovered in 1992 by Dr. Shuguang Zhang of MIT. Our company is globally developing businesses based on various rights associated with self-assembling peptide technology licensed from MIT.
Board Members
- About Us
- Board Members
Chairman and Executive Director Keiji Nagano
After working at ExxonMobil Corporation and then Bain & Company, Nagano started taking
part in New Media as the director of New Media Japan Inc. in 2000. While he was vice-president of the
Tokyo office of Bain & Co., he also played a key role as the director of the South Korea office for
four years in establishing the office. He led projects with clients in various lines of businesses and
gained wide experience in communications, high technology, entertainment, and the healthcare businesses
at Bain & Co.Moreover, he supported foreign capital companies to launch businesses in Japan and
carried them toward success by understanding them at the operational level on the lines.
He graduated from the Faculty of Technology at the University of Tokyo (chemical engineering) and
earned a master’s degree in business economics (MBA) at Columbia University.
President and Representative Director Jun Okada
He started working as a consultant at the Tokyo office of Bain & Co. in 1998, and was
engaged in many projects, including bio investment support for a venture capital company and development
support for a pharmaceutical company (as a resident person for a year). In 2005, he started taking
charge of the corporate planning of 3-D Matrix and took up the post as director in 2007,and assumed his
current position in 2016.
He graduated from the Law Faculty of the University of Tokyo and earned a
master’s degree in business economics (MBA) at the INSEAD in France.
Director(Finance) Tomoyuki Arai
In 1996, He started working at Pronexus Inc. (specialist of supporting corporate disclosure) and was involved in the tasks of many listed companies and those targeting IPOs. Since 2006, he was engaged in consulting services for IPOs and internal control systems at the CSBA consulting group. In 2007, he became a director of CSBA Investment. Subsequently, he was responsible for achieving the IPO (JASDAQ) for Ascot Corp. in 2008. He started serving in the sections for compliance and corporate planning at 3-D Matrix in 2008 and assumed the post of director in July 2012.
Director（Business Development,Japan）Satoru Kobayashi
After working at Fresenius medical care, he started working in the Business development at
3-D Matrix in 2007 and assumed his current position in June 2017.
He graduated Hokkaido University
Graduate School of Medicine.
Director（North America Business）Toshi Amanuma
Toshi started his career at strategy consulting firm Bain & Company, and continued to
gain experience at Sony Corporation, 3-D Matrix and JBIC IG Partners. Recently, he served as managing
director of 3-D Matrix EMEA, responsible for commercializing 3-D Matrix’s first medical device product
across the EMEA region, and as managing director at JBIC IG Partners, a fund GP subsidiary of Japanese
government-owned bank JBIC (Japan Bank of International Cooperation), involved in making fund
investments and leading fund formation projects. Toshi rejoined 3-D Matrix in August 2019 to lead the US
subsidiary, 3-D Matrix, Inc.
Toshi received his MBA from the Tuck School of Business at Dartmouth
College, and his MS from Waseda University.
DirectorRyuhei Mogi
He registered as a lawyer in 1994. After working at a corporate law firm in Tokyo, Linklaters (formerly De Bandt, Van Hecke, Lagae & Loesche), and Oh-Ebashi LPC & Partners, he joined the Company in January 2022. He has been a member of the Board of Directors since July 2023.
Executive Officer (R&D, Europe)Marie Buffier
She obtained her PhD in Biology, Cancer Research & Endocrinology from the Claude Bernard
University of Lyon, France, in 2008. She then worked as a Postdoctoral Research Fellow in USA first at
the Medical Center at University of Rochester and then at the New York University Langone Medical
Center elucidating the mechanisms of inflammation in the esophageal cancer formation.
She joined
3-D Matrix Europe in 2013 as the Project Manager of External collaboration and set-up multiple
collaborations with academics groups and surgeons to expand new applications of 3-D Matrix' peptides
technology. She then lead the development of new products in Europe as the Director of Research and
Development in 2019 and is holding her current position since 2021.
